Enbrel commitment to inflammation care

Anti-TNF agents, including Enbrel, have revolutionised the treatment of chronic inflammatory diseases.1 Pfizer is committed to using our extensive experience and expertise to continue to support and transform the lives of patients living with these debilitating diseases. 

Enbrel has extensive clinical experience across a range of inflammatory diseases2-5

  • Enbrel was the first approved anti-TNF agent for rheumatoid arthritis and is now approved to treat six additional inflammatory conditions:2,6-9
  • Enbrel has over 18 years’ experience with over 5.6 million patient-years exposure*3
  • To date, there have been more than 400 trials conducted with Enbrel and over 7,000 publications*4,5

PP-ENB-GBR-0762. Date of preparation: March 2018

 

*Across all indications.

References 

  1. Vincent FB et al. Ann Rheum Dis. 2013;72:165–178.
  2. Enbrel (etanercept) SmPC. Available at http://www.medicines.org.uk/emc [Accessed March 2018].
  3. Periodic Safety Update Report (PSUR) 22.
  4. Clinical trials for etanercept. Available at http://clinicaltrials.gov [Accessed March 2018].
  5. Pubmed etanercept. Available at https://www.ncbi.nlm.nih.gov/pubmed [Accessed March 2018].
  6. Humira (adalimumab) SmPC. Available at http://www.medicines.org.uk/emc [Accessed March 2018].
  7. Remicade (infliximab) SmPC. Available at http://www.medicines.org.uk/emc  [Accessed March 2018]. 
  8. Cimzia (certolizumab pegol) SmPC. Available at http://www.medicines.org.uk/emc [Accessed March 2018].
  9. Simponi (golimumab) SmPC. Available at http://www.medicines.org.uk/emc  [Accessed March 2018].

Anti-TNF agents, including Enbrel, have revolutionised the treatment of chronic inflammatory diseases.1 Pfizer is committed to using our extensive experience and expertise to continue to support and transform the lives of patients living with these debilitating diseases.

  • The manufacture of original biologics and biosimilars is challenging. Pfizer has over 18 years’ experience manufacturing Enbrel, and fully understands the complex processes involved
  • At the Grange Castle facility where Enbrel is manufactured, Pfizer has amassed extensive expertise in controlling production lines to ensure the consistent delivery of a high quality biologic. To ensure quality:
    • Enbrel has been subject to 19 manufacturing improvements since 19982
    • 20,000 hours of maintenance are performed annually on the quipment used to produce Enbrel2
  • Every batch of Enbrel:
    • Takes 43 days to create2
    • Undergoes >20 testing procedures and 100s of quality control checks2
    • Is produced in state-of-the-art facilities2

Pfizer’s commitment and dedication ensures the manufacture of a high quality biologic for your patients.

TNF: tumour necrosis factor.
 

PP-ENB-GBR-0835. Date of preparation: April 2018

References 

  1. Vincent FB et al. Ann Rheum Dis. 2013; 72:165–178.
  2. Data on file. New York, NY Pfizer Inc. 

Anti-TNF agents, including Enbrel, have revolutionised the treatment of chronic inflammatory diseases.1 Pfizer is committed to using our extensive experience and expertise to continue to support and transform the lives of patients living with these debilitating diseases. 

  • Pfizer is committed to being a trusted partner for healthcare professionals and centres, helping to shape the future of inflammation care2. We are also committed to making a difference to the lives of patients across the UK
  • Pfizer is dedicated to delivering cost-effective and patient-centered care; funding home delivery and patient services to complement and enhance patient care
    • The Together online support programme  was developed in collaboration with Enbrel users. It gives patients content tailored to their condition, administration method and length of time they’ve been taking Enbrel
  • Pfizer aims to provide value for patients, clinicians and commissioners
    • Physicians and those with inflammatory conditions will continue to have access to a medicine they know and trust in a new and changing environment3

See Enbrel's milestone infographic and how we're helping to shape the future of inflammation care.

 

PP-ENB-GBR-0836. Date of preparation: April 2018

 

References 

  1. Vincent FB et al. Ann Rheum Dis. 2013;72:165–178.
  2. Pfizer Pipeline as of April 2015.
  3. www.Pfizer.com.  [Accessed March 2018]